Shridar Ganesan, MD, PhD, on Mutation Burden and Immunotherapy
2017 ASCO-SITC Clinical Immuno-Oncology SymposiumShridar Ganesan, MD, PhD, of the Rutgers Cancer Institute of New Jersey, discusses mutation burden as a biomarker of response to immune checkpoint therapy in nine solid cancers.
Related Videos
Marie-Andrée Forget, PhD, on Metastatic Melanoma: Update From MD Anderson
Marie-Andrée Forget, PhD, of The University of Texas MD Anderson Cancer Center, discusses study findings on the impact of checkpoint blockade prior to adoptive cell therapy using tumo...
Limo Chen, PhD, on Lung Cancer and CD38: Resistance to Immunotherapy
Limo Chen, PhD, of The University of Texas MD Anderson Cancer Center, discusses co-inhibition of CD38 and PD-L1, which leads to improved antitumor immune response, reducing tumor grow...
Holger N. Lode, MD: Neuroblastoma Survival Update
Holger N. Lode, MD, of the University of Greifswald, discusses the survival of neuroblastoma patients treated with long-term infusion of the anti-GD2 antibody ch14.18/CHO and killer-c...
Stephen Gottschalk, MD, on CAR T Cells for Solid Tumors: What Are the Challenges?
Stephen Gottschalk, MD, of Baylor College of Medicine and Texas Children’s Hospital, discusses combining CAR T cells with checkpoint blockade or targeted treatments to improve their a...
Lawrence Fong, MD, on Novel T-Cell Checkpoint Combinations
Lawrence Fong, MD, of the University of California, San Francisco, discusses combination immunotherapy, now approved in melanoma, and the trials underway to explore other indications.
